Cellectis (CLLS) Assets Average (2015 - 2026)
Cellectis (CLLS) posted Assets Average of $307.0 million for Q1 2026, down 8.07% on a QoQ basis from $333.9 million in Q4 2025, and down 17.89% year-over-year from $373.8 million in Q1 2025.
Cellectis (CLLS) has 12 years of Assets Average data on file, last reported at $307.0 million in Q1 2026.
- In Q1 2026, Assets Average fell 17.89% year-over-year to $307.0 million; the TTM figure through Mar 2026 stood at $307.0 million (down 17.89% YoY), while the FY2025 annual figure was $354.1 million, down 1.33% from the prior year.
- Assets Average fell to $307.0 million in Q1 2026, from $333.9 million in the prior quarter.
- Across five years, Assets Average topped out at $401.5 million in Q3 2024 and bottomed at $218.7 million in Q3 2023.
- A 5-year average of $328.8 million and a median of $339.2 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 31.02% — and 2024, when it soared 83.6%.
- Year by year, Assets Average stood at $300.2 million in 2022, then decreased by 9.41% to $272.0 million in 2023, then surged by 43.28% to $389.7 million in 2024, then decreased by 14.33% to $333.9 million in 2025, then retreated by 8.07% to $307.0 million in 2026.
- The last three Assets Average figures came in at $307.0 million (Q1 2026), $333.9 million (Q4 2025), and $348.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 306.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 306.95 Mn |
| Dec 31, 2025 | 333.88 Mn |
| Sep 30, 2025 | 348.51 Mn |
| Jun 30, 2025 | 359.03 Mn |
| Mar 31, 2025 | 373.82 Mn |
| Dec 31, 2024 | 389.71 Mn |
| Sep 30, 2024 | 401.51 Mn |
| Jun 30, 2024 | 380.80 Mn |
| Mar 31, 2024 | 344.36 Mn |
| Dec 31, 2023 | 271.99 Mn |
| Sep 30, 2023 | 218.69 Mn |
| Jun 30, 2023 | 239.54 Mn |
| Sep 30, 2022 | 300.23 Mn |
| Jun 30, 2022 | 334.04 Mn |
| Sep 30, 2021 | 435.23 Mn |
| Jun 30, 2021 | 450.14 Mn |
| Mar 31, 2021 | 456.09 Mn |
| Dec 31, 2020 | 477.21 Mn |
| Sep 30, 2020 | 478.83 Mn |
| Jun 30, 2020 | 471.92 Mn |
| Mar 31, 2020 | 469.30 Mn |
| Dec 31, 2019 | 473.97 Mn |
| Sep 30, 2019 | 492.90 Mn |
| Jun 30, 2019 | 508.63 Mn |
| Mar 31, 2019 | 506.39 Mn |
| Dec 31, 2018 | 510.32 Mn |
| Sep 30, 2018 | 526.93 Mn |
| Jun 30, 2018 | 429.06 Mn |
| Mar 31, 2018 | 328.47 Mn |
| Dec 31, 2017 | 341.14 Mn |
| Sep 30, 2017 | 332.64 Mn |
| Jun 30, 2017 | 320.38 Mn |
| Mar 31, 2017 | 332.18 Mn |
| Dec 31, 2016 | 345.08 Mn |
| Sep 30, 2016 | 357.47 Mn |
| Jun 30, 2016 | 355.66 Mn |
| Mar 31, 2016 | 360.45 Mn |
| Dec 31, 2015 | 354.95 Mn |
| Sep 30, 2015 | 337.82 Mn |
| Jun 30, 2015 | 361.73 Mn |
| Mar 31, 2015 | 277.94 Mn |